Literature DB >> 12379628

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.

R Rau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379628      PMCID： PMC1766697          DOI： 10.1136/ard.61.suppl_2.ii70

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  12 in total

Review 1.  Cytokine pathways and joint inflammation in rheumatoid arthritis.

Authors:  E H Choy; G S Panayi
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

2.  Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

Authors:  P Barrera; L A Joosten; A A den Broeder; L B van de Putte; P L van Riel; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

3.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

Review 4.  Rheumatoid arthritis.

Authors:  D M Lee; M E Weinblatt
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

5.  Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Authors:  P Barrera; A van der Maas; A E van Ede; B A L M Kiemeney; R F J M Laan; L B A van de Putte; P L C M van Riel
Journal:  Rheumatology (Oxford)       Date:  2002-04       Impact factor: 7.580

6.  Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

Authors:  A A den Broeder; L A B Joosten; T Saxne; D Heinegård; H Fenner; A M M Miltenburg; W L H Frasa; L J van Tits; W A Buurman; P L C M van Riel; L B A van de Putte; P Barrera
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

7.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

Authors:  T Saxne; M A Palladino; D Heinegård; N Talal; F A Wollheim
Journal:  Arthritis Rheum       Date:  1988-08

8.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

9.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06

10.  Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.

Authors:  J Saklatvala
Journal:  Nature       Date:  1986 Aug 7-13       Impact factor: 49.962
View more
  35 in total

Review 1.  Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Authors:  M C Hochberg; J K Tracy; M Hawkins-Holt; R H Flores
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.

Authors:  Pablo Sotelo; Noberto Collazo; Roberto Zuñiga; Matías Gutiérrez-González; Diego Catalán; Carolina Hager Ribeiro; Juan Carlos Aguillón; María Carmen Molina
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

3.  The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy.

Authors:  Lori A Coburn; Paul E Wise; David A Schwartz
Journal:  Dig Dis Sci       Date:  2006-09-29       Impact factor: 3.199

4.  A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.

Authors:  Mateus Dalcin Luchese; Mariana Lopes Dos Santos; Angelica Garbuio; Roselaine Campos Targino; Carla Ploeger Mansueli; Lilian Rumi Tsuruta; Wagner Quintilio; Ana Maria Moro
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

5.  NMR-based structural validation of therapeutic antibody produced in Nicotiana benthamiana.

Authors:  Hirokazu Yagi; Noriho Fukuzawa; Yasushi Tasaka; Kouki Matsuo; Ying Zhang; Takumi Yamaguchi; Sachiko Kondo; Shiori Nakazawa; Noritaka Hashii; Nana Kawasaki; Takeshi Matsumura; Koichi Kato
Journal:  Plant Cell Rep       Date:  2015-02-18       Impact factor: 4.570

6.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 7.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

Review 8.  The immunological contribution to heterotopic ossification disorders.

Authors:  Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

9.  Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.

Authors:  Annamaria Iagnocco; Chiara Perella; Esperanza Naredo; Gary Meenagh; Fulvia Ceccarelli; Emanuela Tripodo; Stefania Basili; Guido Valesini
Journal:  Clin Rheumatol       Date:  2007-10-19       Impact factor: 2.980

10.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.